26 May 2016 -  NICE has released an appraisal consulation document for necitumumab for untreated advanced or metastatic, squamous non-small-cell lung cancer.

Necitumumab, in combination with gemcitabine and cisplatin, is not recommended within its marketing authorisation for treating locally advanced or metastatic epidermal growth factor receptor expressing squamous non-small-cell lung cancer that has not been treated with chemotherapy, in adults.

A second appraisal committee meeting will be held on 29 June 2016; final guidance is due in September.

For more details, go to: https://www.nice.org.uk/guidance/indevelopment/gid-ta10009/consultation/html-content